ECSS
SMMT icon

Eurizon Capital SGR SpA’s Summit Therapeutics SMMT Stock Holding History

Eurizon Capital SGR SpA’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,908
Closed -$131K – 1279
2026
Q1 		$131K Sell
6,908
-18,754
-73% -$303K ﹤0.01% 828
2025
Q4 		$449K Buy
+25,662
New +$483K ﹤0.01% 589

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Eurizon Capital SGR SpA's SMMT Position: Q2 2026 in Review

Eurizon Capital SGR SpA sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 6,908 shares — an estimated $131K sold.

Eurizon Capital SGR SpA first reported a position in SMMT in Q4 2025 and held it in 2 quarters. The position peaked at $449K in Q4 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Eurizon Capital SGR SpA reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Eurizon Capital SGR SpA sold 6,908 Summit Therapeutics shares in Q2 2026, an estimated $131K.
  • Eurizon Capital SGR SpA first reported a position in Summit Therapeutics in Q4 2025 and held it in 2 quarters.
  • Eurizon Capital SGR SpA's Summit Therapeutics position peaked at $449K in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.